ライフサイエンスコーパス: endpoint

1 8-coRPGR), meeting the pre-specified primary endpoint.

2 ence at a long-term timepoint as the primary endpoint.

3 nt, and overall survival was a key secondary endpoint.

4 radiomics signature was calculated for each endpoint.

5 n each individual component of the composite endpoint.

6 rials manifesting a smooth trajectory to the endpoint.

7 ority of the groups for the primary efficacy endpoint.

8 5%) met the primary and 4 (5%) the secondary endpoint.

9 and overall survival (OS) was the secondary endpoint.

10 asive mechanical ventilation was the primary endpoint.

11 iple was applied for analysis of the primary endpoint.

12 usly reported non-inferiority at the primary endpoint.

13 nd give rise to freezing of gait as clinical endpoint.

14 2 mg group met the primary and all secondary endpoints.

15 cerebrospinal fluid parameters and clinical endpoints.

16 mpletion) or safety (readmissions and death) endpoints.

17 s study did not meet either of its coprimary endpoints.

18 ndpoints or Kappa statistics for categorical endpoints.

19 o PM(2.5) can lead to improvements in health endpoints.

20 ty, with exploratory efficacy and immunology endpoints.

21 dels were used to estimate and compare study endpoints.

22 ects of prevention on venous thromboembolism endpoints.

23 ry embolism, and major bleeding as secondary endpoints.

24 ed by biomarkers and, rarely, actual disease endpoints.

25 matter and the hippocampus were evaluated as endpoints.

26 hylaxis episodes were evaluated as secondary endpoints.

27 sed to identify risk factors for the primary endpoint, 28-day mortality, among hospitalized patients.

28 To ensure that endpoint accuracy was unaffected by tremor, we quantifie

29 iding the emergence of complex developmental endpoints across different scales of time.

30 rnational study, using translational imaging endpoints, aimed to examine the neuroprotective effects

31 The secondary endpoints analysed within this report include safety, ov

32 The primary endpoint, analysed in all participants who were randomly

33 members of the interim analysis and primary endpoint analysis data monitoring teams) remained masked

34 FORWARD-5 achieved the primary endpoint and demonstrated that adjunctive BUP/SAM 2 mg/2

35 the use of unbiased estimates of IBD segment endpoints and a pedigree-based genetic map.

36 l objective with the study design, including endpoints and analysis.

37 tional hazard models for time-to-first event endpoints and Cochran's Q test for treatment interaction

38 any quantification of the uncertainty in the endpoints and lengths of the IBD segments.

39 roved endoscopic, radiographic, and clinical endpoints and patient-reported outcomes.

40 and secondary outcomes included 30-day major endpoints and procedural complications.

41 chemia, or thrombotic bailout at 96 h (4-way endpoint) and the composite of death or MI at 30 days.

42 30-day all-cause mortality (ACM) (secondary endpoints), and time to negative blood culture.

43 y with respect to the primary cardiovascular endpoint, and its long-term use is not associated with a

44 Disease-free survival (DFS) was the primary endpoint, and overall survival (OS) was the secondary en

45 ework, taking overall mortality as a primary endpoint, and pulmonary embolism, fatal pulmonary emboli

46 ration (primary endpoint) or other secondary endpoints are observed.

47 lity, advantages, and disadvantages of these endpoints are summarised, with recommendations on clinic

48 ed an independent reduction in the composite endpoint at 14-days controlling for other factors (adjus

49 The primary endpoint at week 48 was HIV-1 RNA >=50 copies per mL (Sn

50 Since oxytocin reduced the primary endpoint, Autism Diagnostic Observation Schedule (ADOS)

51 or drug selection, and lack of translational endpoints between animals and humans contributed to prio

52 grade, HIV co-infection status, and clinical endpoints by 3 months were recorded.

53 ships between sTNFR1 and renal and mortality endpoints by multivariable linear mixed-effects models a

54 Secondary endpoints: clinical response, all-cause mortality, and t

55 The secondary composite endpoint combining overall recurrent melioidosis and mor

56 ndomized to oral antibiotics met the primary endpoint compared with 72/78 (92.3%) randomized to intra

57 Endpoints consisted of (i) technical efficacy; primary -

58 We quantified the endpoint control of these contractions, gray matter (GM)

59 < .001) to piperacillin/tazobactam for both endpoints: day 28 all-cause mortality was 15.9% with imi

60 0 days), 77% of patients had a study-related endpoint (death 32%, discharge 45%).

61 Secondary endpoints did not reveal any significant group differenc

62 vascularization (a device-oriented composite endpoint [DOCE]).

63 ed in the first 11 months, and the secondary endpoints (efficacy by baseline serostatus, serotype, ho

64 ease (DKD) conventionally define a surrogate endpoint either as a percentage of decrease of eGFR (e.g

65 71.5 months (IQR 71.3 to 71.7), the primary endpoint event occurred in 79 patients (31 in the 40 Gy

66 Primary endpoint: favorable overall response (defined by relevan

67 met statistical significance for their main endpoint, five for increased intervention-associated mor

68 hed statistical significance for the primary endpoint for all patients and the subset with LGI1-IgG.

69 simplify complex antibody data and an ideal endpoint for desensitization trials.

70 The primary endpoint for Ewing sarcoma was best objective response w

71 strates that lipid metabolism is a sensitive endpoint for the interacting environmental effects of pr

72 orable overall response (defined by relevant endpoints for each infection type) in the modified micro

73 summarised, with recommendations on clinical endpoints for the different phase trials, including limi

74 The co-primary efficacy endpoints for the intention-to-treat population were inv

75 ive elicited neutralizing antibodies with an endpoint geometric mean titer of ~415 against replicativ

76 after 8-day functional monotherapy (primary endpoint); here we report planned interim analyses throu

77 Although graft loss is a primary endpoint in many studies in kidney transplantation and a

78 Photoreceptor loss is the final common endpoint in most retinopathies that lead to irreversible

79 or death before recurrence), an exploratory endpoint in Short-HER.

80 oxytocin was only elevated from baseline to endpoint in the oxytocin-group compared with the placebo

81 ificant improvement in the primary composite endpoint in the PP population but not in the mITT popula

82 from trials within the Intermediate Clinical Endpoints in Cancer of the Prostate-ICECaP-database with

83 Primary endpoints in the COLOR and COLOR II trial were disease-f

84 The safety endpoint included the major adverse neurological or card

85 Secondary endpoints included 6-item asthma control questionnaire (

86 y lipoprotein cholesterol (LDL-C); secondary endpoints included achievement of LDL-C <70 mg/dl and pe

87 Secondary endpoints included all-cause mortality, non-procedural m

88 -year follow-up, respectively, and secondary endpoints included anastomotic leakage rate.

89 Study endpoints included AR progression, asthma progression, a

90 The secondary endpoints included body mass index (BMI), glucose contro

91 Secondary endpoints included fatigue, sexual function, and safety

92 te response rate (CRR) per RECIST; secondary endpoints included feasibility, metabolic response, toxi

93 Secondary endpoints included incidence of community-onset healthca

94 Study endpoints included radial alveolar counts (RACs), vessel

95 Secondary endpoints included safety (determined by major bleeding

96 Secondary endpoints included the Hamilton Anxiety Scale (HAM-A), H

97 Secondary endpoints included the proportion of patients achieving

98 Secondary endpoints included the proportion of patients who had an

99 The secondary endpoints included virological suppression at 48 weeks a

100 has been associated with a variety of health endpoints including cardiovascular disease, sleep distur

101 We discuss how early and intermediate endpoints, including patient-reported outcomes and invol

102 on for heart failure; we also assessed these endpoints individually and assessed all-cause mortality.

103 mycological eradication) at day 14 (primary endpoint), investigator-assessed clinical response at da

104 The primary endpoint is the proportion of patients with a refractive

105 The primary endpoint (MACE) comprised death of CAD, nonfatal myocard

106 cell population averages and are mostly time endpoint measurements and thus provide no temporal infor

107 tion of patients, control interventions, and endpoint measures.

108 low-up HRCT, the proportion with ILD events (endpoint met or radiographic ILA progression) was calcul

109 hese points is associated with the pseudogap endpoint near optimal doping.

110 responders that ultimately failed and early endpoint non-responders that ultimately succeeded were s

111 prospective, randomised, open-label, blinded-endpoint, non-inferiority trial of febuxostat versus all

112 The primary composite endpoint occurred in 17.5% (50/286) of all patients and

113 sis estimates the relative risk of the Ebola endpoint occurring from after the blood draw through to

114 equal to 40 was associated with the primary endpoint (odds ratio, 1.94; 95% CI, 1.18-3.18; p = 0.009

115 ulder pain and function (OSS) at the primary endpoint of 12 months were less than the target differen

116 ment onset; for osteosarcoma, a dual primary endpoint of 6-month objective response and 6-month non-p

117 superiority versus adalimumab in the primary endpoint of ACR20 response at week 52.

118 The primary endpoint of bone metastasis-free survival was not signif

119 y versus conventional therapy on the primary endpoint of cardiovascular death or hospital admission f

120 ng follow-up (median 516 days), the combined endpoint of cardiovascular death, all-cause stroke, myoc

121 ups were evaluated, with a primary composite endpoint of escalation of care from ward to intensive ca

122 ability of nGA for the conventional clinical endpoint of geographic atrophy (GA) as defined on color

123 The primary endpoint of mRS at day 90 did not differ between each of

124 significantly associated with the composite endpoint of nonrebreather or higher oxygen requirement a

125 or to retinal ganglion cell (RGC) death, the endpoint of optic neuropathy.

126 Here, we report the secondary endpoint of overall survival results for the RANGE trial

127 e, we report findings for the second primary endpoint of population uptake of HIV prevention services

128 dulator laquinimod did not reach the primary endpoint of reduction in confirmed disability progressio

129 Here we report the key secondary efficacy endpoint of the proportion of participants who achieved

130 The primary clinical endpoint of the study was mortality at Day 28.

131 The primary endpoint of this study was the occurrence of pulmonary e

132 Seven endpoints of cytotoxicity were recorded.

133 Meta-analyses involving endpoints of interest were performed when feasible.

134 effects of probiotics for any of the study's endpoints on those complying with the hospital guideline

135 70-182) used a paired t test for continuous endpoints or Kappa statistics for categorical endpoints.

136 changes in tumor cell proliferation (primary endpoint) or other secondary endpoints are observed.

137 inning 30 days post-second dose, the primary endpoint (overall vaccine efficacy) was assessed in the

138 The primary endpoints (overall survival and progression-free surviva

139 reporting included having PROs as a primary endpoint (p=0.008) and the presence of a subsequent publ

140 on are in vivo models, making the choice of endpoint parameters a key element in evaluating the sens

141 Results were confirmed by endpoint PCR and Sanger sequencing, which revealed muscl

142 Across all studies, surrogate endpoints predominated as outcomes, followed by biomarke

143 -DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomi

144 Here, we report the results of a secondary endpoint, quality of life, of the LACC trial.

145 nd isoprenaline separately produced clinical endpoints related to diabetic cardiomyopathy, the combin

146 for new leprosy case detection and secondary endpoints related to operational classification and lepr

147 Progression-free survival, the primary endpoint, remained significantly improved for the D-VMP

148 The proportions of early endpoint responders that ultimately failed and early end

149 The primary endpoints (safety in GEN501 and overall response rate in

150 patients with data available for the primary endpoints; safety analysis included all randomly assigne

151 f future coastal flooding frequency focus on endpoint scenarios, such as the increase in flooding by

152 tient selection criteria, safety monitoring, endpoint selection, and more.

153 Analysis of secondary endpoints showed efficacies of 76.1% (95% CI 68.5 to 81.

154 d, the force impulse after insertion and the endpoint stiffness magnitude decreased as a function of

155 ITT necrotizing infection clinical composite endpoint success was 48.6% reltecimod versus 39.9% place

156 The specific endpoints that were responsive to exposure in each gener

157 erformance of a novel hierarchical composite endpoint, the Alive and Ventilator Free score.

158 The primary endpoint, the GBS disability scale at 4 weeks, was asses

159 The study met its primary endpoint: the fixed-dose combination of pertuzumab and t

160 roved inconsistent across several behavioral endpoints thought to be dependent on dentate neurogenesi

161 Efficacy was maintained for most endpoints through week 52.

162 efficient method for quantifying IBD segment endpoint uncertainty is implemented in the open source i

163 mprehensive review of clinical and surrogate endpoints used in trials for non-metastatic rectal cance

164 Our study links DNA methylation to disease endpoints via intermediate proteomics phenotypes and ide

165 The primary endpoint was 1-year tumor-death censored graft and patie

166 The primary endpoint was 28-day mortality after ICU admission.

167 The primary endpoint was 30-day image-confirmed IAA.

168 The primary endpoint was 6-month total body weight loss (TBWL).

169 Our primary endpoint was a composite of cardiovascular death or firs

170 The primary endpoint was a composite of nonfatal AMI, unscheduled re

171 Primary endpoint was a composite of occurrence of death or new o

172 The primary endpoint was a prostate-specific antigen response in rel

173 The primary endpoint was a recurrence of negative remodeling, define

174 The primary endpoint was abdominal pain response, as defined by the

175 The primary endpoint was all-cause mortality, or discharge from hosp

176 The primary endpoint was all-cause mortality.

177 The primary endpoint was American College of Rheumatology 20% improv

178 The primary endpoint was assessed in the intention-to-treat analysis

179 he study eye, and the key secondary efficacy endpoint was bacterial eradication, both at the day 5 vi

180 The primary endpoint was biopsy-confirmed acute rejection (BCAR) wit

181 The primary efficacy endpoint was change from the 4-week observation period i

182 The primary endpoint was change in total motor score from baseline t

183 The primary endpoint was clinical cure assessed at week 12 and inclu

184 The primary efficacy endpoint was clinical outcome (responder rate) on day 14

185 The primary endpoint was clinical resolution in the study eye, and t

186 The primary endpoint was death or retransplant during the first year

187 The primary endpoint was detection of minimal residual disease (MRD)

188 Primary endpoint was disease-free survival (DFS), secondary endp

189 Drug Administration-defined primary efficacy endpoint was early clinical response 48-72 hours after t

190 The primary endpoint was event-free survival (EFS), and secondary en

191 The primary endpoint was fever clearance time (FCT); secondary endpo

192 The primary endpoint was first manifestation of CAV diagnosed by cor

193 The primary endpoint was independent review facility-assessed progre

194 he European Medicines Agency-defined primary endpoint was investigator-assessed clinical success at t

195 The primary endpoint was investigator-assessed objective response ra

196 The primary endpoint was investigator-assessed overall response (at

197 The primary endpoint was investigator-assessed progression-free surv

198 The primary endpoint was investigator-assessed progression-free surv

199 The primary endpoint was investigator-assessed progression-free surv

200 The key secondary endpoint was investigator-assessed response rate in the

201 The primary endpoint was major adverse cardiac or cerebrovascular ev

202 The primary endpoint was major adverse cardiac or cerebrovascular ev

203 The primary endpoint was major pathological response, defined as the

204 t 12 months after randomization, the primary endpoint was met in 6 (12%) DJBL patients and 3 (10%) co

205 The primary endpoint was met: ACR20 at week 24 was achieved by signi

206 The primary endpoint was non-inferiority of the cycle 7 pertuzumab s

207 In the mITT population, the primary endpoint was not significantly different between the azi

208 The primary endpoint was objective response rate (ORR); the null hyp

209 The primary endpoint was objective response rate based on the 2007 I

210 The primary endpoint was objective response, defined as complete and

211 The primary endpoint was overall response rate after up to eight tre

212 The primary endpoint was overall response rate.

213 The primary effectiveness endpoint was procedural success.

214 The primary endpoint was progression-free survival assessed by blind

215 The primary endpoint was progression-free survival assessed by inten

216 The primary endpoint was progression-free survival by independent re

217 The primary endpoint was progression-free survival with a one-sided

218 The primary endpoint was progression-free survival, and all analyses

219 The primary endpoint was progression-free survival, assessed by BICR

220 The primary endpoint was rate of overall survival at 3 months (OS3).

221 The primary endpoint was reached in 101 (8.7%) patients in the ticag

222 The primary endpoint was recurrence-free survival by investigator as

223 The primary endpoint was recurrence-free survival, analysed in the p

224 The primary endpoint was resolution of NASH.

225 The primary endpoint was response to treatment (P2Y(12) reaction uni

226 The primary endpoint was safety and we observed 6 of 28 patients (21

227 The proportion experiencing the primary endpoint was similar in the vaccine and placebo groups,

228 The primary endpoint was survival at 1 year after durable MCS implan

229 The primary efficacy endpoint was sustained virologic response 12 weeks after

230 The primary endpoint was sustained virological response 12 weeks aft

231 The primary endpoint was the ability of coronary CTA to rule out cor

232 The primary endpoint was the change in the Epworth Sleepiness Scale

233 The primary endpoint was the composite of cardiac death, target vess

234 Primary endpoint was the difference in maximum walking distance

235 The primary endpoint was the incidence of treatment-emergent adverse

236 The primary efficacy endpoint was the mean rate of change in GA over 12 month

237 The main endpoint was the occurrence of HCC.

238 The primary endpoint was the percent change (baseline to week 24) in

239 The primary efficacy endpoint was the proportion of participants who had a pl

240 The primary endpoint was the proportion of patients achieving a 50%

241 The primary endpoint was the proportion of patients with undetectabl

242 The primary efficacy endpoint was the proportion of subjects with an AC cell

243 Primary endpoint was the rate of SSI within 30 days postoperativ

244 The primary endpoint was the remission of MS at 12 months.

245 The primary endpoint was the resolution of NASH without worsening of

246 The primary endpoint was the time until full coverage of the posteri

247 The primary endpoint was time to all-cause death.

248 The primary endpoint was time to recovery, defined as return to usua

249 The primary endpoint was time to the first protocol-defined relapse,

250 The primary endpoint was total HIV DNA isolated from peripheral bloo

251 The primary endpoint was week 12 change from baseline in PASI score.

252 Primary endpoints were adverse events (grade 3 or higher) and do

253 Secondary endpoints were antimicrobial consumption, in-hospital mo

254 nalysis of pooled MODIFY I/II data, efficacy endpoints were assessed in participants infected with re

255 and measurement of cytokine levels; primary endpoints were cervical T cell activation, vaginal micro

256 treatment-emergent adverse events; secondary endpoints were changes in LDL-C and other lipids.

257 The primary endpoints were clinical remission at week 16 and endosco

258 Primary endpoints were confirmed objective response rate in all

259 Primary endpoints were determination of dose-limiting toxicities

260 Secondary endpoints were duration of response, disease control rat

261 The primary endpoints were event-free survival, overall response, an

262 The study endpoints were extracted and compared, with the risk of

263 Primary endpoints were improvement of IBS symptoms and bloating

264 Primary endpoints were maximum tolerated dose, recommended phase

265 Since the primary endpoints were met at the first interim analysis, update

266 All prespecified endpoints were met.

267 Both primary endpoints were met: ASAS40 at week 16 (ixekizumab Q4W: 3

268 Secondary endpoints were Mf clearance at 6, 12, and 24 months; ina

269 The secondary endpoints were not in favour of a second IVIg course.

270 s after 24 weeks of treatment, however trial endpoints were not met after 48 weeks.

271 The co-primary endpoints were overall response and maximum trough conce

272 Primary endpoints were overall survival (OS) and disease-specifi

273 t was disease-free survival (DFS), secondary endpoints were overall survival (OS) and local control (

274 The coprimary endpoints were overall survival and imaging-based progre

275 The two primary endpoints were overall survival for durvalumab plus plat

276 Key secondary endpoints were overall survival, event-free survival, an

277 The secondary endpoints were progression-free survival (PFS) and overa

278 Dual primary efficacy endpoints were progression-free survival and overall sur

279 The endpoints were rebleeding and rebleeding/transplantation

280 Coprimary endpoints were risk of the composite outcome of blood tr

281 Co-primary endpoints were safety (assessed by incidence of adverse

282 The primary endpoints were safety and immunogenicity at day 42 after

283 Primary endpoints were safety and infectivity of the new isolate

284 Primary endpoints were safety and tolerability, and 12-week dise

285 Primary endpoints were safety and tolerability, with exploratory

286 Endpoints were solicited/unsolicited and serious adverse

287 Secondary endpoints were survival and inflation-adjusted hospital

288 Endpoints were the composite of death, myocardial infarc

289 Main endpoints were the detection rate (DR) and false-negativ

290 The primary endpoints were the effects of dietary and pharmacologica

291 Secondary endpoints were the effects of S44819 on the NIHSS and Mo

292 Secondary endpoints were the ICU length of stay and the 28-day all

293 Endpoints were time to parasitemia, adverse events, and

294 was event-free survival (EFS), and secondary endpoints were toxicity and predictors of EFS and overal

295 Secondary endpoints were treatment failure (biopsy-proven acute re

296 nt was fever clearance time (FCT); secondary endpoints were treatment failure and adverse events.

297 Secondary endpoints were: hemispheric space-modifying edema, infar

298 hresholds, analyzed separately as co-primary endpoints, were AUC/MIC by broth microdilution >=650 and

299 Mayo endoscopy subscore, 0 or 1) improvement endpoint, which we called histo-endoscopic mucosal heali

300 el identified patients who met the composite endpoint with an AUC of 0.90, the GBS with an AUC of 0.8